AVE1642

DRUG3 trials

Sponsors

Sanofi

Conditions

Breast NeoplasmsLiver CarcinomaMultiple Myeloma

Phase 1

Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma

TerminatedNCT00791544

SanofiLiver Carcinoma

Start: 2008-11-30End: 2009-11-30Updated: 2010-08-04

Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma

CompletedNCT01233895

SanofiMultiple Myeloma

Start: 2006-09-30End: 2008-09-30Updated: 2010-11-03

Phase 2

Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer

TerminatedNCT00774878

SanofiBreast Neoplasms

Start: 2008-10-31End: 2010-11-30Updated: 2011-03-03